Comparison of Different Doses of Clonidine to Fentanyl as an Adjuvant to Bupivacaine 0.5% for Spinal Anesthesia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the safety, quality and duration of block with the addition of Clonidine in different doses to 0.5% heavy bupivacaine, and to compare it with addition of Fentanyl to 0.5% heavy bupivacaine in sub- arachnoid block.
| Condition | Intervention |
|---|---|
|
Full Term Pregnant Patients Undergoing Lower Segment Caesarian Section |
Drug: Fentanyl Drug: Clonidine Drug: clonidine |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized Clinical Study to Compare Different Doses of Clonidine to Fentanyl as an Adjuvant to Hyperbaric Bupivacaine 0.5% for Spinal Anesthesia in Patients Undergoing LSCS |
- Duration of block [ Time Frame: 6 hours ] [ Designated as safety issue: No ]Measured by regression of sensory block by 2 dermatomal segments and residual motor blockade monitored by wearing off time (when patient starts to lift legs against gravity)
- Demographic characteristics [ Time Frame: 15 Minutes ] [ Designated as safety issue: No ]Age,Height,Weight,Duration of Pregnancy etc.
- Maternal safety [ Time Frame: 24 Hours ] [ Designated as safety issue: Yes ]Measured by parameters like pulse rate, respiratory rate, SpO2, blood pressure and blood loss.
- Maternal side effects [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]Side effects such as nausea, vomiting, pain, shivering, pruritis, sedation,urinary retention and respiratory discomfort will be observed.
- Foetal safety [ Time Frame: 20 Minutes ] [ Designated as safety issue: Yes ]Indicated by APGAR Scores
- Quality of block [ Time Frame: 15 Minutes ] [ Designated as safety issue: No ]Sensory by pinprick method, and Motor by modified Bromage scale
- Duration of postoperative analgesia [ Time Frame: 24 Hours ] [ Designated as safety issue: No ]Measured by Visual Analogue Scores and time at which first rescue analgesia dose is required.
| Estimated Enrollment: | 80 |
| Study Start Date: | August 2010 |
| Estimated Study Completion Date: | November 2011 |
| Estimated Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: BF25 (Control)
GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
|
Drug: Fentanyl
GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
Other Name: Fentanyl
|
|
Experimental: BC15(Study 1)
GROUP BC15 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
|
Drug: Clonidine
In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
Other Name: Clonidine
|
|
Experimental: BC30(Study 2)
GROUP BC30 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
|
Drug: Clonidine
In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
Other Name: Clonidine
|
|
Experimental: BC60 (Study 3)
GROUP BC60 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
|
Drug: clonidine
In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
Other Name: Clonidine
|
Detailed Description:
All the patients selected for study will have a detailed general examination including airway assessment, spine, and systemic examination .Patient will be kept nil-by-mouth for 6 to 8 hours. Sedatives and hypnotics will be avoided in premedication as well as intraoperatively.All patients will be premedicated with antiemetic agent - Inj ondansetron(4 mg). In O.T. patient will be preloaded with R.L. 10-15 mL/kg.Pre-operative parameters like pulse rate, respiratory rate, oxygen saturation and blood pressure will be noted.
Procedure
Spinal anaesthesia will be given with 25G Quinke's needle in sitting position. Under all aseptic precautions and depending upon the groups, respective agents will be injected intrathecally.That is Group BC15 will be given 2ml of hyperbaric bupivacaine 0.5%with 15 mcg clonidine intrathecally; Group BC30 will be given 2ml of hyperbaric bupivacaine 0.5% with 30 mcg clonidine intrathecally;Group BC60 will be given 2ml of hyperbaric bupivacaine 0.5% with 60 mcg clonidine intrathecally Group BF25 will be given 2ml of hyperbaric bupivacaine 0.5% with 25mcg of fentanyl intrathecally.Each group will have a total volume of 2.5 ml made by addition of Normal saline Both the patient and anesthesiologist will be blinded to the study solutions. Syringes will be prepared immediately before the spinal injection ensuring the volumes at 2.5ml by third person knowing the code to blind the Anaesthesiologist administering the drug and later on making the observations. Pulse and blood pressure will be measured every 5 minutes for first 30minutes and thereafter every 10 minutes.Sensory block will be tested by pinprick method. Degree of motor blockade will be assessed by modified Bromage scale. In the intraoperative period, patient will be closely monitored for pulse rate, respiratory rate, SpO2, blood pressure and blood loss.
- Any side effects such as nausea, vomiting, pain, shivering, pruritis, sedation hypotension, bradycardia,urinary retention and respiratory discomfort will be noted and treated with appropriate drugs. Inj oxytocin 10U will be added to R.L. after delivery of anterior shoulder. Residual sensory blockade will be monitored and its wearing off time will be noted(when sensation to pin-prick regresses by 2 dermatomal segments).
- Residual motor blockade will be monitored and its wearing off time will be noted(when patient starts to lift legs against gravity) Post operative analgesic drugs will be given when patient's VAS score reaches > 7. (this will be taken as the time of wearing off analgesia) and the time of injection of first analgesic drug.(Inj Voveran 75mg i.m.)will be noted.VAS involves us of a 10cm line on a piece of white paper and it represents patients opinion of degree of pain.It will be explained to all patients preoperatively that one end of the line i.e '0' marks "no pain" at all, while other end i.e '10' represents "worst pain" she ever felt. Patient will rate the degree of pain by making a mark on the scale. Thus the pain score will be obtained by measuring the distance from the '0' end to the indicated mark.
Pain score 0-3 mild 3-7 moderate >7 severe The various data obtained, including different parameters measured at different time intervals, will be calculated and compared with baseline values within each group as well as with corresponding times among the groups, using appropriate test of significance. p value less than 0.05 will be taken as significant. The data will be presented by constructing various tables and graphs.
Eligibility| Ages Eligible for Study: | 20 Years to 35 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Undergoing Lower Segment Caesarian Section
- ASA grade I or II
- Not having any complicated pregnancy
- Not having any systemic disorders.
- Age group 20 - 35 years
Exclusion Criteria:
- Not willing for spinal anaesthesia
- Unwilling to get enrolled in this study.
- Complicated pregnancy like pregnancy induced hypertension, placenta previa, abruptio placenta.
- Systemic disorders like diabetes, heart disease, chronic hypertension, pulmonary disease
- With acute fetal distress.
- With bleeding or coagulation disorders.
- Maternal haemorrhage leading to hypovolemia.
- Height less than 145 cms
Contacts and Locations| Principal Investigator: | Dr.Mrs. Bhavini B Shah, MBBS DA | Pravara Institute of Medical Sciences |
| Principal Investigator: | Dr.Mrs.Smita S Joshi, MD DA | Pravara Institute of Medical Sciences |
More Information
No publications provided
| Responsible Party: | Dr.Mrs.Bhavini Shah, Pravara Institute of Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT01205204 History of Changes |
| Other Study ID Numbers: | abcd123 |
| Study First Received: | September 15, 2010 |
| Last Updated: | September 23, 2010 |
| Health Authority: | India: Institutional Review Board |
Keywords provided by Pravara Institute of Medical Sciences University:
|
Clonidine Fentanyl Bupivacaine Spinal Anesthesia Lower Segment Caesarian Section |
Additional relevant MeSH terms:
|
Anesthetics Bupivacaine Fentanyl Clonidine Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Anesthetics, Local Sensory System Agents Peripheral Nervous System Agents Antihypertensive Agents Cardiovascular Agents |
Sympatholytics Autonomic Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Analgesics Adjuvants, Anesthesia Narcotics Anesthetics, Intravenous Anesthetics, General Analgesics, Opioid |
ClinicalTrials.gov processed this record on May 19, 2013